Gene · 4921
Papers2,653
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,461 to 1,480 of 2,653
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma. | Mol Oncol | 2019 | 31116512 | PubTator, text mining | PubMed |
| The current state of molecular testing in the treatment of patients with solid tumors, 2019. | CA Cancer J Clin | 2019 | 31116423 | PubTator, text mining | PubMed |
| Methylation and PTEN activation in dental pulp mesenchymal stem cells promotes osteogenesis and reduces oncogenesis. | Nat Commun | 2019 | 31110221 | PubTator, text mining | PubMed |
| Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma. | J Int Med Res | 2019 | 31106632 | PubTator, text mining | PubMed |
| Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway. | BMC Cancer | 2019 | 31092229 | PubTator, text mining | PubMed |
| Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung. | Nat Commun | 2019 | 31086186 | PubTator, text mining | PubMed |
| Transgenerational sperm DNA methylation epimutation developmental origins following ancestral vinclozolin exposure. | Epigenetics | 2019 | 31079544 | PubTator, text mining | PubMed |
| Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy. | Int J Mol Sci | 2019 | 31075880 | PubTator, text mining | PubMed |
| Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. | J Mol Diagn | 2019 | 31075511 | PubTator, text mining | PubMed |
| miR-186 Suppresses the Progression of Cholangiocarcinoma Cells Through Inhibition of Twist1. | Oncol Res | 2019 | 31072421 | PubTator, text mining | PubMed |
| Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary Lesions. | Front Oncol | 2019 | 31069172 | PubTator, text mining | PubMed |
| Data-Driven Analysis of Age, Sex, and Tissue Effects on Gene Expression Variability in Alzheimer's Disease. | Front Neurosci | 2019 | 31068785 | PubTator, text mining | PubMed |
| Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies. | Int J Mol Sci | 2019 | 31067787 | PubTator, text mining | PubMed |
| MT1-MMP-dependent cell migration: proteolytic and non-proteolytic mechanisms. | Biochem Soc Trans | 2019 | 31064864 | PubTator, text mining | PubMed |
| Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment. | Mol Cell Proteomics | 2019 | 31061140 | PubTator, text mining | PubMed |
| Mono(2-ethylhexyl) phthalate (MEHP) induces transcriptomic alterations in oocytes and their derived blastocysts. | Toxicology | 2019 | 31059758 | PubTator, text mining | PubMed |
| Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. | Breast Cancer Res | 2019 | 31046834 | PubTator, text mining | PubMed |
| Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer. | Mol Cancer Res | 2019 | 31043489 | PubTator, text mining | PubMed |
| Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. | Cancers (Basel) | 2019 | 31035693 | PubTator, text mining | PubMed |
| Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers. | JAMA Netw Open | 2019 | 31026031 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4921/papers?page=74